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Abstract 
Methotrexate concentration was analyzed in a number of tissues of a patient of osteogenic sarcoma
who had been on high-dose methotrexate therapy for nearly 6 months. Gall bladder and kidney
contained the highest concentration of the drug, followed by testis, small intestine, skeletal muscle,
bone marrow, lung, spleen, heart and liver, Although, compared to kidney the liver contained relatively
small amount of the drug, yet nearly 115th of the total drug in liver was in bound form, This bound
form of methotrexate is most likely associated with multiple forms of dihydrofolate reductase. The total
concentration of methotrexate in kidney is 80 fold higher than the concentration of the drug in liver and
28 fold higher than the concentration in bone marrow. This suggests that in high-dose methotrexate
therapy,nephrotoxicityis the more immediate threat to the patient than hepatotoxicity and bone marrow
suppression (JPMA 4&341 ,1998).
Introduction 
Antifolate drug methotrexate (MTX) has wide application in the treatment of a variety of neoplasms1.
It is widely used in high dosages along with “leucovorin rescue” in the treatment of osteogemc sarcoma
This therapy has been quite effective2-8, however, occasional reports of clinical toxicity do appear in
the literature4,9. Despite extensive use of the drug in the treatment of cancer, data pertaining to its
accumulation in various human tissues is scanty especially after high dosage protocols10,11. In this
paper, we report the accumulation of MTX in human tissues alter multiple cycles of high-dose MTX in
a patient suffering from osteogenic sarcoma.
Patients and Methods 
Tissue samples were provided by the University of California at Los Angles Center for Health
Sciences, Los Angeles, of a patient who died of metastatic osteogenic sarcoma. This patient was a 16
year old boy and was being treated with 4-hour infusions of MTX (200 mg/kg). He had received
thirteen cycles of MTX over a period of six months. Each infusion of the drug was preceded by
intravenous hydration and urinary alkalinization and Ca leucovorin rescue was initiated 4 hours
following the completion of MTX infusion. A week following the last infusion, the patient died of
sepsis. An autopsy was performed and tissue specimens of liver, kidney, spleen, bone marrow, heart,
skeletal muscle, jejunum, thyroid, lung, testis and gall bladder were obtained for analysis of free and
protein-bound MTX.
Tissues were rinsed with cold 0.15 M NaCI and dried on a filter paper. A piece of each tissue was
weighed and homogenized in a homogenizer using 3 volumes of 0.06 M citrate buffer, pH 7.4 per gram
of tissue using a procedure described by Rothenberg et al12. The homogenate was centrifuged at
30,000xg for 15 ruin and the supernatant solution was divided into two parts. One part was subjected to
exhaustive dialysis overnight against 0.06 M citate buffer, pH 7.4 containing an anion exchange resin
Ag 2x8 (Bio-Rad Laboratories) and the non-dialyzable MTX in the dialysand was assayed by a
sensitive ligand binding radioassay13. Total MTX in the other half (not subjected to dialysis) was also
determined by the same procedure. Protein concentration in the cytoplasmic contents of the tissues was
determined by the method of Lowry et al14. Hemoglobin contents in some of these tissues (bone
marrow, heart, spleen and skeletal muscle) were determined by the benzidine method15 and subtracted
from the total protein concentration of that particular tissue.
Results 
Table shows the free and the protein-bound MTX concentration values in the cytoplasmic samples of
various human tissues: Highest levels of the drug were found in gall bladder, kidney and testis, while
jejunum, skeletal muscle and bone marrowhadlevelsbetween86 ng -110 ngpermgprotein. Liver, spleen,
lung and heart did not show a substantial uptake of the drug.
Discussion 
High levels of the drug in gallbladder, kidney and small intestine are consistent with the findings of
Anderson et al10 who have shown kidney and gall bladder having the drug concentration more than any
other tissue in the body. This is further supported by various models of MTX pharmacokinetics
showing elimination of the drug mainly through kidney and biliary secretion16, therefore, most of the
drug was expected to be present in the kidney and the gall bladder. Because of high levels of plasma
MTX due to repeated infusions, othertissues such as heart, skeletal muscle, lungs and thyroid did show
accumulation of the drug to some degree. This may suggest that at highplasma levels of the drug, the
tissues generally spared at low plasma levels of the drug still permit drug intake probably by passive
diffusion. Since there is usually very little dihydrofolate reductase (the principal binding detenninant of
MTX) inside these tissues17, only a small component of the total drug is in the bound form, whereas
most of the drug is in the free state. On the other hand, liver compared to other tissues has been shown
to have the maximum amount of dihydmfolate reductase17,18 and therefore, nearly 1/5thofthetotal drug
inliverwas foundtobe in the bound form. Since the amount of enzyme in most human es ineluding liver
has been repoited to be less than 0.08 nmol/gm of it is unlikely that all of the protein-bound MDC is in
association with high affinity form of dilry drofolate reductase.
This alludes to the presence of a form of dihydrofolate reductase having low affinity for MTX. We have
reported earlierthepresenceof such aformofenzymeinnormal human colon20 and goat liver21 High dose
methotrexate therapy is now being increasingly used in Pakistan18,19,22. Although short-term renal
toxicity and hematological and mucosal toxicities are prevented by hydration and alkalinization of
urine with NaHCO3 and leucovonn rescue, respectively, yet repeated exposure to high doses of MTX
may lead to serious toxic effects due to the accumulation of the drug in various tissues of the body.
These side-effects originate primarily because of the inhibition of de novo DNA synthesis.
Because of an 80-fold higher accumulation of total MTX mthe kidney compared to the liver(Table), itis
plausible that the chance of nephrotoxicity would be much higher than hepatotoxicity, once multiple
cycles of the drug have been administered. This observation is consistent with the results by Pitman et
al. who have reported that 60% of their patients on high-dose MTX experience a serum creatinine
elevation of more than 50%23. Similarly, the concentration of total MTX in kidney was found to be 28
times more than the concentration of the drug in bone marrow. This again suggests that nephmtoxicity
is more likely to occur first in such patients than bone marrow suppression. Another important
observation of this study was a very high concentration of MTX in the bile. Biliary excretion of MTX
in humans after an intravenous injection of the drug has been reported19,24. However, there is not much
information available on accumulation of the drug inbile after repeated cycles of therapy. Bile,
therefore, could serve as a reservoir of the drug leading to a continuous supply of the drug for several
hours after an infusion of MTX and thereby, contributing towards the adverse effect of the therapy. A
more detailed investigation on a large number of patients receiving high-dose MDC would be required
to have a betterunderstanding of the associated toxic effects.
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